Related to Figures 3, 4 and 6
[DOI] [PMC free article] [PubMed] [Google Scholar] 44.Mamoulakis D., Galanakis E., Dionyssopoulou E., Evangeliou A., Sbyrakis S
If you experience dizziness, faint, abdominal pain, and vomiting after getting the injection, inform your doctor immediately
Engineered to activate glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, Retatrutide has shown promising preclinical results in studies of metabolic regulation, weight management, and glycemic control
By activating these receptors, the medication may inadvertently alter the signaling of neurotransmitters involved in sleep
A Phase 2 substudy analyzing body composition found that retatrutide produced up to 26.1% reduction in total body fat mass while limiting lean mass loss to approximately 6.5kg